Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: September 2014

Chapter 8 - Cardiac diseases relevant to stroke

from Section 2: - Clinical epiderminology and risk factors

Related content

Powered by UNSILO


1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155:469–73.
2. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28:973–7.
3. Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004; 25:1734–40.
4. Liao J, Khalid Z, Scallan C, et al. Non-invasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke. A systematic review. Stroke 2007; 38:2935–40.
5. Wallmann D, Tüller D, Wustmann K, et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients. An opportunity for a new diagnostic strategy. Stroke 2007; 38:2292–4.
6. Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke 2008; 39:480–2.
7. Spring M, Dorian P, Fry B, et al. A 30-day cardiac event monitor belt for recording paroxysmal atrial fibrillation after a cerebral ischemic event. The EMBRACE Pilot Study. Stroke 2008; 39:571–2.
8. Cotter PE, Martin PJ, Ring L, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013; 80:1546–50.
9. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374:534–42.
10. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127:720–9.
11. Stöllberger C, Chnupa P, Kronik G, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998; 128:630–8.
12. Stöllberger C, Schneider B, Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. Chest 2003; 124:2356–62.
13. Moro C, Crampes F, Sengenes C, et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J 2004; 18:908–10.
14. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57:160–6.
15. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2004; 10:221–6.
16. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112:307–13.
17. Oppenheimer S. Cerebrogenic cardiac arrhythmias: cortical lateralization and clinical significance. Clin Auton Res 2006; 16:6–11.
18. Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 2007; 49:320–8.
19. Tatschl C, Stöllberger C, Matz K, et al. Insular involvement is associated with QT prolongation: ECG abnormalities in patients with acute stroke. Cerebrovasc Dis 2006; 21:47–53.
20. Fure B, Bruun Wyller T, Thommessen B. Electrocardiographic and troponin T changes in acute ischemic stroke. J Intern Med 2006; 259:592–7.
21. Dhamoon MS, Tai W, Boden-Albala B, et al. Risk of myocardial infarction or vascular death after first ischemic stroke. The Northern Manhattan Study. Stroke 2007; 38:1752–8.
22. Gongora-Rivera F, Labreuche J, Jaramillo A, et al. Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke. Stroke 2007; 38:1203–10.
23. Hankey GJ, Majrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000; 31:2080–6.
24. Barber M, Morton JJ, Macfarlane PW, et al. Elevated troponin levels are associated with sympathoadrenal activation in acute ischemic stroke. Cerebrovasc Dis 2007; 23:260–6.
25. Jensen JK, Kristensen SR, Bak S, et al. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 2007; 99:108–12.
26. Finsterer J, Stöllberger C, Krugluger W. Cardiac and noncardiac, particularly neuromuscular, disease with troponin-T positivity. Neth J Med 2007; 65:289–95.
27. Vaitkus PT, Barnathan EX. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993; 22:1004–9.
28. Zielinska M, Kaczmarek K, Tylkowski M. Predictors of left ventricular thrombus formation in acute myocardial infarction treated with successful primary angioplasty with stenting. Am J Med Sci 2008; 335:171–6.
29. Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE prospective cohort study (ICE-PCS). Am Heart J 2007; 154:1086–94.
30. Cabell CH, Pond KK, Peterson GE, et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J 2001; 142:75–80.
31. Anderson DJ, Goldstein LB, Wilkinson WE, et al. Stroke location, characterization, severity, and outcome in mitral vs aortic valve endocarditis. Neurology 2003; 61:1341–6.
32. Thuny F, Avierinos JF, Tribouilloy C, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J 2007; 28:1155–61.
33. Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354–61.
34. Schulz R, Werner GS, Fuchs JB, et al. Clinical outcome and echocardiographic findings of native and prosthetic valve endocarditis in the 1990s. Eur Heart J 1996; 17:281–8.
35. Ruttmann E, Willeit J, Ulmer H, et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke 2006; 37:2094–9.
36 Barsic B, Dickerman S, Krajinovic V, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 2013; 56:209–17.
37. Ruel M, Masters RG, Rubens FD, et al. Late incidence and determinants of stroke after aortic and mitral valve replacement. Ann Thorac Surg 2004; 78:77–84.
38. Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation. J Am Coll Cardiol 2008; 51:1203–11.
39. Kulik A, Bédard P, Lam BK, et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg 2006; 30:485–91.
40. Will MB, Bernacca GM, Bell EF, et al. Our inability to predict thromboembolic events after prosthetic valve surgery. J Heart Valve Dis 2006; 15:570–80.
41. Cabanes L, Coste J, Derumeaux G, et al. Interobserver and intraobserver variability in detection of patent foramen ovale and atrial septal aneurysm with transesophageal echocardiography. J Am Soc Echocardiogr 2002; 15:441–6.
42. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318:1148–52.
43. Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale. The PFO-ASA Study. Stroke 2002; 33:706–11.
44. Homma S, Sacco RL, Di Tullio MR, et al.; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105:2625–31.
45. Di Tullio MR, Sacco RL, Sciacca RR, et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 2007; 49:797–802.
46. Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 2006; 47:440–5.
47. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366:991–9.
48. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368:1092–100.
49. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368:1083–91.
50. Abaci A, Unlu S, Alsancak Y, et al. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv 2013; 82:1123–38. doi: 10.1002/ccd.24875.
51. Stöllberger C, Finsterer J, Krexner E, et al. Stroke and peripheral embolism from an Amplatzer septal occluder 5 years after implantation. J Neurol 2008; 255:1270–1.
52. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45:969–81.
53. Gibelin P. Anticoagulant treatment and dilated cardiomyopathy. Arch Mal Coeur Vaiss 1995; 88(Suppl 4):617–21.
54. Crawford TC, Smith WT 4th, Velazquez EJ, et al. Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death. Am J Cardiol 2004; 93:500–3.
55. Abreu TT, Mateus S, Correia J. Therapy implications of transthoracic echocardiography in acute ischemic stroke patients. Stroke 2005; 36:1565–6.
56. Ikeniwa C, Sakai M, Kimura S, et al. Two cases of Duchenne muscular dystrophy complicated with dilated cardiomyopathy and cerebral infarction. No To Shinkei 2006; 58:250–5.
57. McCabe DJ, Rakhit RD. Antithrombotic and interventional treatment options in cardioembolic transient ischemic attack and ischemic stroke. J Neurol Neurosurg Psychiatry 2007; 78:14–24.
58. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366:1859–69.
59. Stöllberger C, Finsterer J. Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy. Clin Cardiol 2007; 30:375–80.
60. Artz G, Wynne J. Restrictive cardiomyopathy. Curr Treat Options Cardiovasc Med 2000; 2:431–8.
61. Salih MA, Al-Jarallah AS, Abdel-Gader AG, et al. Cardiac diseases as a risk factor for stroke in Saudi children. Saudi Med J 2006; 27(Suppl 1):S61–8.
62. Hausfater P, Costedoat-Chalumeau N, Amoura Z, et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol 2005; 34:315–19.
63. Stöllberger C, Finsterer J, Schneider B. Tako-tsubo-like left ventricular dysfunction: clinical presentation, instrumental findings, additional cardiac and non-cardiac diseases and potential pathomechanisms. Minerva Cardioangiol 2005; 53:139–45.
64. Abe Y, Kondo M, Matsuoka R, et al. Assessment of clinical features in transient left ventricular apical ballooning. J Am Coll Cardiol 2003; 41:737–42.
65. Gianni M, Dentali F, Grandi AM, et al. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 2006; 27:1523–9.
66. Ueyama T, Senba E, Kasamatsu K, et al. Molecular mechanism of emotional stress-induced and catecholamine-induced heart attack. J Cardiovasc Pharmacol 2003; 41(Suppl 1):S115–18.
67. Finsterer J, Stöllberger C, Sehnal E, et al. Apical ballooning (Takotsubo syndrome) in mitochondrial disorder during mechanical ventilation. J Cardiovasc Med (Hagerstown) 2007; 8:859–63.
68. Porto I, Della Bona R, Leo A, et al. Stress cardiomyopathy (tako-tsubo) triggered by nervous system diseases: A systematic review of the reported cases. Int J Cardiol 2013; 167:2441–8.
69. Mitsuma W, Kodama M, Ito M, et al. Thromboembolism in Takotsubo cardiomyopathy. Int J Cardiol 2010; 139:98–100.
70. Stöllberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr 2004; 17:91–100.
71. Stöllberger C, Winkler-Dworak M, Blazek G, et al. Prognosis of left ventricular hypertrabeculation/noncompaction is dependent on cardiac and neuromuscular comorbidity. Int J Cardiol 2007; 121:189–93.
72. Stöllberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol 2002; 90:899–902.
73. Finsterer J, Stöllberger C, Blazek G. Prevalence of Barth syndrome in adult left ventricular hypertrabeculation/noncompaction. Scand Cardiovasc J 2008; 42:157–60.
74. Stöllberger C, Blazek G, Dobias C, et al. Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction. Am J Cardiol 2011; 108:1021–3.
75. Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis: still a mystery after 60 years. PLoS Negl Trop Dis 2008; 2:e97.
76. Sarazin M, Caumes E, Cohen A, et al. Multiple microembolic borderzone brain infarctions and endomyocardial fibrosis in idiopathic hypereosinophilic syndrome and in Schistosoma mansoni infestation. J Neurol Neurosurg Psychiatry 2004; 75:305–7.
77. Gautier JC, Dürr A, Koussa S, et al. Paradoxical cerebral embolism with a patent foramen ovale. A report of 29 patients. Cerebrovasc Dis 1991; 1:193–202.
78. Stöllberger C, Slany J, Schuster I, et al. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Ann Intern Med 1993; 119:461–5.
79. Ranoux D, Cohen A, Cabanes L, et al. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke 1993; 24:31–4.
80. Itoh T, Matsumoto M, Handa N, et al. Paradoxical embolism as a cause of ischemic stroke of uncertain etiology. A transcranial Doppler sonographic study. Stroke 1994; 25:771–5.
81. Hanna JP, Sun JP, Furlan AJ, et al. Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke 1994; 25:782–6.
82. Klötzsch C, Janßen G, Berlit P. Transesophageal echocardiography and contrast-TCD in the detection of a patent foramen ovale: experiences with 111 patients. Neurology 1994; 44:1603–6.
83. Rohr-Le Floch J. Foramen ovale perméable et embolie paradoxale: une hypothèse controversée. Rev Neurol (Paris) 1994; 150:282–5.
84. Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997; 80:1066–9.
85. Cramer SC, Rordorf G, Maki JH, et al. Increased pelvic vein thrombi in cryptogenic stroke. Results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) Study. Stroke 2004; 35:46–50.